(Q24246118)

22 October 2023

Chuanfang Lee

1

C

Lee

1 reference

22 October 2023

Yan Gong

series ordinal

2

author given names

Y

author last names

Gong

1 reference

22 October 2023

Jesper Brok

series ordinal

3

author given names

J

author last names

Brok

1 reference

22 October 2023

Elizabeth H Boxall

series ordinal

4

author given names

E H

author last names

Boxall

1 reference

Cochrane Database of Systematic Reviews

22 October 2023

language of work or name

1 reference

19 April 2006

0 references

published in

0 references

cites work

Neonatal deaths after hepatitis B vaccine: the vaccine adverse event reporting system, 1991-1998.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Passive-active immunization in infants of hepatitis Be antigen-positive mothers. Comparison of the efficacy of early and delayed active immunization

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Vaccines for preventing hepatitis B in health-care workers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Hepatitis B prophylaxis for newborns of hepatitis B surface antigen-positive mothers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Five-year follow-up of a prospective randomized trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: Immunogenicity and anamnestic responses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Twelve-year follow-up of a prospective randomized trial of hepatitis b recombinant DNA yeast vaccine versus plasma-derived vaccine without booster doses in children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Multicenter trial on the efficacy of HBIG and vaccine in preventing perinatal hepatitis B. Final report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Immunoprophylaxis of perinatal transmission of the hepatitis B virus: efficacy of hepatitis B immune globulin and hepatitis B vaccine in a low-prevalence area

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Dynamics and impact of perinatal transmission of hepatitis B virus in North India

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Prevention of perinatal transmission of hepatitis B Virus (HB V): A comparison of two prophylactic schedules

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Review: protective efficacy of hepatitis B vaccines in neonates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Characterization of a human monoclonal antibody obtained after immunization with plasma vaccine and a booster with recombinant-DNA hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Methods for combining randomized clinical trials: strengths and limitations.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Hepatitis B virus infection in pregnant mothers and its transmission to infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Simultaneous administration of hepatitis B vaccine with other E.P.I. vaccines

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Safety and immunogenicity of a yeast-derived recombinant hepatitis B vaccine in Bulgarian newborns

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Prevention of hepatitis B infection in infants born to hepatitis B carrier mothers: low dosage vaccination

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Cost-effectiveness of hepatitis B vaccine in The Gambia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Hepatitis B immunization of newborns according to a two dose protocol.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

A 5-year immunization field trial against hepatitis B using a Chinese hamster ovary cell recombinant vaccine in French Polynesian newborns: results at 3 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Hepatitis B vaccination: universal vaccination of newborn babies and children at 12 years of age versus high risk groups. A comparison in the field

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

A follow-up study of combined vaccination with plasma-derived and recombinant hepatitis B vaccines in infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis B virus--the case of Belgium

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis-B vaccine and hepatitis-B immunoglobulin. Double-blind randomised placebo-controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Hepatitis B immunisation with a reduced number of doses in newborn babies and children

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Prevention of hepatitis B virus carrier state in infants according to maternal serum levels of HBV DNA.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Evaluation of a low dose of hepatitis B vaccine given within a childhood immunisation programme in Singapore

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Efficacy and safety of recombinant hepatitis B vaccine in infants born to HBsAg-positive mothers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Use of the hepatitis B recombinant DNA yeast vaccine (H-B-VAX II) in children: two doses vs. three doses of 5 micrograms regime; an interim report

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Japanese and American reports of randomized trials: differences in the reporting of adverse effects

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Comparative efficacy, safety and immunogenicity of Hepavax-Gene and Engerix-B, recombinant hepatitis B vaccines, in infants born to HBsAg and HBeAg positive mothers in Vietnam: an assessment at 2 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Over a decade of experience with a yeast recombinant hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Adverse events associated with hepatitis B vaccine in U.S. children less than six years of age, 1993 and 1994.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

The long-term efficacy of plasma-derived hepatitis B vaccine in babies born to carrier mothers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Hepatocellular Carcinoma and Hepatitis B Virus

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Vertical Transmission of Hepatitis B Antigen in Taiwan

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

e antigen and anti-e in the serum of asymptomatic carrier mothers as indicators of positive and negative transmission of hepatitis B virus to their infants

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

An efficacy trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine in infants born to mothers positive for HBsAg, in Shanghai, China

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Postnatal infectivity of hepatitis B surface antigen-carrier mothers.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Long-term efficacy of active postexposure immunization of infants for prevention of hepatitis B virus infection. United States-People's Republic of China Study Group on Hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

The e antigen and vertical transmission of hepatitis B surface antigen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Use of hepatitis B vaccine alone or in combination with hepatitis B immunoglobulin for immunoprophylaxis of perinatal hepatitis B infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

The protective efficacy of recombinant hepatitis B vaccine in newborn infants of hepatitis B e antigen-positive-hepatitis B surface antigen carrier mothers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Combined active-passive immunization against the hepatitis B virus: five-year follow-up of children born to hepatitis B surface antigen-positive mothers.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Recombinant hepatitis B vaccination of neonates and infants: emerging safety data from the Vaccine Adverse Event Reporting System

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Safety of neonatal hepatitis B vaccine administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Long-term immunoprophylaxis of hepatitis B surface antigen carrier in infants born to hepatitis B surface antigen positive mothers using plasma derived vaccine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): a decision analytic approach to cost effectiveness

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Screening assays for transmissible spongiform encephalopathies (TSEs).

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Passive-active immunisation of neonates of HBsAg positive carrier mothers: preliminary observations

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Interaction revisited: the difference between two estimates

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Preventing and treating hepatitis B infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Long-term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Controlled trial of immune response of preterm infants to recombinant hepatitis B and inactivated poliovirus vaccines administered simultaneously shortly after birth

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Perinatal transmission of hepatitis B virus infection and vaccination in China

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Routine prenatal screening of Indian women for HBsAg: benefits derived versus cost

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Hypotonic-hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS), 1996-1998.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Risk of Anaphylaxis After Vaccination of Children and Adolescents

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Quantifying adverse drug events : are systematic reviews the answer?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Operating characteristics of a rank correlation test for publication bias

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Evaluating non-randomised intervention studies

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Interruption of HBV intrauterine transmission: a clinical study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004790.PUB2

7 January 2021

10.1002/14651858.CD004790.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

5063544

Fatcat ID

release_ybmdznngo5c7ximo5mvm6prn24

0 references

OpenCitations bibliographic resource ID

5063544

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

5063544